Brokers Offer Predictions for GPCR Q1 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q2 2027 earnings at ($0.59) EPS.

GPCR has been the subject of several other reports. Citizens Jmp reiterated a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings upgraded shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Trading Down 5.3%

NASDAQ GPCR opened at $19.84 on Friday. Structure Therapeutics has a 1 year low of $18.70 and a 1 year high of $94.90. The company has a market cap of $1.38 billion, a PE ratio of -15.38 and a beta of -1.12. The stock’s 50-day moving average price is $28.43 and its two-hundred day moving average price is $46.40.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15).

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC grew its stake in Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after acquiring an additional 102,929 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Orbimed Advisors LLC lifted its position in shares of Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after purchasing an additional 313,600 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Structure Therapeutics in the second quarter worth approximately $1,041,000. Finally, SEB Asset Management AB purchased a new stake in shares of Structure Therapeutics in the first quarter worth approximately $11,811,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.